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Abstract—Targeted molecular therapies opened new ways
and increased the efficiency of cancer therapies. Antiangiogenic
therapy focuses against the growth of tumor by blocking the
blood vessel formation of it. Its control engineering perspective
has been presented several times, but its key point represents
modeling the tumor growth. The purpose of our research is to
go beyond the already published minimalistic approach and set
up a bi-compartmental (vasculature-dependent tumor growth
and angiogenesis) model. The aim of the current paper is to
extend our recently published dynamical bicompartmetal model
to include the effect of not only for antiangiogenic, but also
cytotoxic drugs as well as input. We compare the effect of
the two different inputs on the model dynamics in the context
of final tumor volume, which can be used as a measure of
therapy effectiveness. According to the model prediction, the
combination of drugs is more efficient compared to either mono-
therapy. Furthermore, we compare an optimized open-loop
protocol with a very simple intuitive feedback therapy solution.
I. INTRODUCTION
Although the process called angiogenesis, in which the
growing tumor induces the formation of new blood vessels
to support the high metabolic needs of proliferating cells, is
well known since the 70’s [1], the therapeutic implications of
this process are still under intensive development [2]. Recent
results [3] have shown that innovative treatment protocol
designs (e.g. in the simplest case only the more distributed in-
jection of the same or less dosage of medicine) of antiangio-
genic drugs may enhance the effectiveness of antiangiogenic
treatments. This is not surprising, since the effect of various
drugs is different in the various phases of tumor growth.
Discriminating between different phases of tumor vasculature
development, we have to mention the concept of the so called
angiogenic switch [4], which refers to the time instance at
which the size of the tumor makes no longer possible to cover
its metabolic needs from diffusion from the environment
and thus, if some (partially still unknown) conditions are
present, angiogenesis is initiated. If antiangiogenic drugs are
provided before the angiogenic switch, their effectiveness
is questionable if their concentration is not large enough
to maintain a steady serum level for the following period.
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Moreover, the consideration that antiangiogenic drugs have
less effect after the majority of the supporting vasculature
has been already evolved seems plausible.
The question of optimal protocols and optimal dosage
naturally arises from the above considerations. On the one
hand, it is not clear how to define a general protocol for
the administration of a certain antiangiogenic drug; while
on the other hand, it is even less clear how to curtail such
a protocol for the individual and its unique features in the
implementation of such a therapy. The field of theoretical
biology proposes the tool of predictive computational models
to provide insights into these questions. Namely, several
computational models have been formulated to describe the
process of tumorous angiogenesis, and those models may
serve as bases for therapy design [5], [6]. An even more chal-
lenging question is how to combine antiangiogenic therapy
with a conventional cytotoxic therapy (i.e. chemotherapy) to
achieve maximal efficiency [7].
As also underlined in the EU directive [8], in the process
of experimentation required for obtaining such an optimal
therapy, it is necessary to minimize the number of labora-
tory animals used for experiments. Simulation models may
provide valuable hypotheses, thus may help to design more
successful experiments in this context.
While an ’optimal’ therapy is unquestionably desirable,
and computational models may undoubtedly help to design
such a protocol, at the application level additional questions
arise. As tumors themselves are very heterogenous, and so
are the patients, a theoretically ’optimal’ therapy may not
work perfectly at the level of a specific patient.
Regarding the process of tumor-related vascularization,
several imaging techniques have been published recently,
which may serve as basis for the spatial reconstruction of
vasculature networks. Functional photoacoustic microscopy
[9] and doppler optical frequency domain imaging [10] are
already used today in in vivo setups to analyze vascular
networks, while diffusible iodine-based contrast-enhanced
computed tomography [11] may be used in terminal ex-
perimental animals. However, although the application of
these methods in e.g. immuno-suppressed animals should be
carried out with precautions, these methods definitely have
the potential to gather data of pathological vascularization
during tumor growth.
With the development of these methods, and other bio-
chemical (vascularization-related tumor) markers, it is plau-
sible to assume that important data of the vascularization will
be available for measurement. If we assume that the sam-
pling time is small enough, based on the developed optimal
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therapies, closed-loop solutions may provide the robustness
and flexibility required for the most efficient application of
computer-controlled drug administration. Potential benefits
of discrete-time controller based treatments over protocol-
based cancer therapies is discussed in [12]. This approach
has already been successfully applied in the case of diabetes
in the concept of artificial pancreas [13], [14], [15], [16].
Recently, we developed a concentrated-parameter dynamic
model for the description of the growth of a tumor and
its supporting vasculature [17]. The main aim during the
synthesis of this model was to capture the fundamental
phenomena related to vasculature-dependent tumor growth
and angiogenesis, and simultaneously keep the complexity
level of the model low enough to make it able to serve as a
basis for control and optimization-related methods.
In this paper, we first provide a simple extension of the
above mentioned bi-compartmental model with an additional
input to make it capable for the differentiated description of
cytotoxic drugs in addition to antiangiogenic drugs, which
was the original input of the model. After the short discussion
of the model equations and their extension, we demonstrate
that the two inputs (the antiangiogenic drug input and the
cytotoxic drug input) influence the dynamics of the model
in significantly different ways. Following this, we formulate
and solve a dosage-optimization problem for the combined
therapy, using both inputs of the model. Finally, we compare
the open-loop results to an intuitively defined very simple
closed-loop approach.
II. MATERIALS AND METHODS
As mentioned in the previous section, the original form
of the following model was introduced in [17]. The basic
concept of the model is that it differentiates between two
compartments of the tumor called core (lower index C in
the equations) and periphery (lower index P ). The core
represents the inside of the tumor, the cells which need
the pathological vasculature to get nutrient access, while the
periphery represents the proliferating outer layer which is
capable to get metabolic resources from the environment via
diffusion.
A. Model Equations
The state equations used in this article are as follows:
dr
dt
= a1g([TP ]) (1)
dTC
dt
=
dVC
VP
TP − a2fnecr([NC ])TC
−γCDT [CTD]TC (2)
dTP
dt
= −
dVC
VP
TP + a3fprol([NP ], [TP ])TP
−γCDT [CTD]TP (3)
dTNC
dt
= a2fnecr([rC ])TC + γCDT [CTD]TC (4)
dWC
dt
= a4r
β dVC
VP
WP +
(a5e
−[AI]γAI )fTAF ([NC ])WP (5)
dWP
dt
= dVT ν(r)− a4r
β dVC
VP
WP
+(a5e
−[AI]γAI )fTAF ([NC ])WP (6)
d[AI ]
dt
= −cAI [AI ] + IAI(t) (7)
d[CTD]
dt
= −cCTD[CTD] + ICTD(t) , (8)
where r represents the radius of the tumor, TC and TP
denote the number of living tumor cells in the tumor core and
in the periphery, TNC stands for the number of necrotized
tumor cells in the core, WC ,WP denote the volume of
vasculature in the core and the volume of vasculature in the
periphery, and [AI] and [CTD] represent the concentration
of the angiogenic inhibitor and the cytotoxic drug. The actual
tumor volumes of the core and the periphery are denoted with
the auxiliary variables VC and VP which may be derived
from the variable r, as described in [17]. For dimensions
of parameters and state variables of the model, the reader
may refer to [17] as well. The actual volume increment of
the core is dVC , while the actual volume increment of the
tumor is dVT . Square brackets always denote concentration
(or density). The variables IAI and ICTD denote the injection
rates of the angiogenic inhibitor and the cytotoxic drug
respectively, considered as inputs to the system.
Comparing this set of model equations with the original
model in [17], the difference is the presence of the cytotoxic
drug: the state equation (8) was not included in the original
model, and the terms including the γCDT multiplier (rep-
resenting the efficiency of the cytotoxic drug) in equations
(2), (3) and (4) are new as well. These terms represent
the assumption that the cytotoxic drug initiates tumor cell
death both in the core and in the periphery. We assume that
necrotized tumor cells in the core are accumulated.
[NC ] and [NP ] denote the nutrient concentration of the
core and the periphery respectively, as dimensionless nor-
malized variables, which may be calculated as:
[NC ] =
rC
r
ref
V
[NP ] =
rP
r
ref
V
, (9)
where rC =
WC
VC
, rP =
WP
VP
and r
ref
V is the reference
vasculature ratio, defining the necessary percentage of blood
vessels in a unit volume of tissue to sufficiently support
tumor cells with nutrients.
The only new parameter is γCDT , whose value is assumed
to be 0.45. This value of the parameter implies that similar
concentrations of the two drugs have similar magnitude of
effect on tumor-inhibition.
The values of the other parameters, as well as the
form of the nonlinear functions g([TP ]), fprol([NP ], [TP ]),
fnecr([rC ]), fTAF ([NC ]) may be found in [17].
III. RESULTS
A. Comparision of the qualitative effect of the model inputs
1) One-shot therapy: In this subsection, we analyze and
compare the qualitative properties and effects of the model
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inputs, assuming a one-shot monotherapy, namely we assume
a protocol in which only one injection is administered from
any of the drugs. We assume that the dose injected is 5
units ([mg/kg]). Figure 1 depicts the final volume (volume
on final day 21) of the tumor as the function of one-shot
administration time of the drug. For sake of comparison, the
reference final tumor size (if no drug is administered) is 5848
mm3. Fig. 1 demonstrates that assuming one-shot monother-
apy, both of the drugs (AA-antiangiogenic, CT-cytotoxic)
affect the growth of the tumor on a similar magnitude, and
both of them have an optimal administration time instance.
Furthermore, the model predicts that the angiogenic inhibitor
is more sensitive to the exact time of administration, and that
the optimal administration time of the cytotoxic drug can be
found slightly later compared to the antiangiogenic drug (in
accordance with medical knowledge).
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Fig. 1. The final tumor volume as a function of the administration time,
assuming one-shot monotherapy with a dose of 5 units in the case of the
antiangiogenic (AA) and cytotoxic (CT) drug.
On the other hand, we may compare how the final tumor
volume depends on the administered dose. Figure 2 depicts
these results assuming that the corresponding dose is admin-
istered on day 11 in order to achieve maximal effect. As
we can see in these figures, the effect of the antiangiogenic
drug is more saturating, while the effect of the cytotoxic
drug depends more in a linear fashion on the administered
quantity (again, in accordance with medical knowledge).
B. Interaction of drugs
If we apply both antiangiogenic and cytotoxic drug shots
of 5 units at day 11, the simulation results in a final volume
of 2924 mm3, which clearly shows that the combination of
the two drugs – according to model prediction – is more
effective compared to the monotherapies. In fact, in Fig. 2,
we can see that applying 10 units of the cytotoxic drug -
which is the more effective at this dose -, compared to the
5-5 units of AA and CT, results in a final volume about 3600
mm3.
This can be explained by the saturation phenomena. If we
individually increase the dose of either drug without applying
the other, the increase of effect above a certain dose will not
0 5 10 15 20
applied dose [mg/kg]
2500
3000
3500
4000
4500
5000
5500
fin
al
 tu
m
or
 v
ol
um
e 
[m
m3
]
AA
CT
Fig. 2. The final tumor volume as a function of the administered dose,
assuming one-shot 21-day long monotherapy, where the administration time
is day 11. The monotherapy was investigated for antiangiogenic (AA) and
cytotoxic (CT) drug.
follow the increase of dose anymore, as it can be seen in
Fig. 2. Furthermore, antiangiogenic drug has the potential
to normalize the pathological tumor vasculature (vascular
remodeling) and hence the cytotoxic drug can exerts its effect
more efficiently [18], [19].
C. Open-loop protocols
In the following, we investigate discrete treatment proto-
cols where a combination of antiangiogenic and cytotoxic
drugs is administered for the patient in given days.
As both the cytotoxic and antiangiogenic drugs are typi-
cally available as injections, and we assume outpatients, the
number of days on which the patient must visit the hospital to
get these injections can be considered as a critical parameter
of the therapy, also significantly reflecting the load on the
healthcare system.
In the following, considering fixed numbers of treatment
days, we analyze how the treatment schedule and the distri-
bution of the drug dosage among treatment days affects the
efficiency of the therapy.
Table I summarizes the notations for the analyzed treat-
ment schedules which were determined based on the follow-
ing practical considerations:
• We assume 2-6 treatment days
• The interval between any two treatment days should be
at least 2 days.
• We assume that in the initial period of tumor growth
the tumor is unnoticed, thus the treatment may begin at
earliest on day 6.
• Based on the results depicted in Fig. 1, we may con-
clude that injections in the final phase of the tumor
growth are not efficient, thus we assume that the last
possible day for any schedule is day 16.
• We assume that the total injection quantity for the
therapy is 5 units for both drugs.
• The minimal dose of injection is 0.1.
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schedule days schedule days
S1 [6, 8] S30 [8, 12, 16]
S2 [6, 10] S31 [8, 14, 16]
S3 [6, 12] S32 [10, 12, 14]
S4 [6, 14] S33 [10, 12, 16]
S5 [6, 16] S34 [10, 14, 16]
S6 [8, 10] S35 [12, 14, 16]
S7 [8, 12] S36 [6, 8, 10, 12]
S8 [8, 14] S37 [6, 8, 10, 14]
S9 [8, 16] S38 [6, 8, 10, 16]
S10 [10, 12] S39 [6, 8, 12, 14]
S11 [10, 14] S40 [6, 8, 12, 16]
S12 [10, 16] S41 [6, 8, 14, 16]
S13 [12, 14] S42 [6, 10, 12, 14]
S14 [12, 16] S43 [6, 10, 12, 16]
S15 [14, 16] S44 [6, 10, 14, 16]
S16 [6, 8, 10] S45 [6, 12, 14, 16]
S17 [6, 8, 12] S46 [8, 10, 12, 14]
S18 [6, 8, 14] S47 [8, 10, 12, 16]
S19 [6, 8, 16] S48 [8, 10, 14, 16]
S20 [6, 10, 12] S49 [8, 12, 14, 16]
S21 [6, 10, 14] S50 [10, 12, 14, 16]
S22 [6, 10, 16] S51 [6, 8, 10, 12, 14]
S23 [6, 12, 14] S52 [6, 8, 10, 12, 16]
S24 [6, 12, 16] S53 [6, 8, 10, 14, 16]
S25 [6, 14, 16] S54 [6, 8, 12, 14, 16]
S26 [8, 10, 12] S55 [6, 10, 12, 14, 16]
S27 [8, 10, 14] S56 [8, 10, 12 ,14, 16]
S28 [8, 10, 16] S57 [6, 8, 10, 12, 14, 16]
S29 [8, 12, 14]
TABLE I
VARIOUS TREATMENT SCHEDULES TESTED FOR OPEN-LOOP THERAPY
OPTIMIZATION
We compared two cases for each treatment schedule. In the
first case we assumed that the drugs are evenly distributed
among the days of the therapy; while in the second case,
we assumed an optimal drug dosage. The optimal dosage
problem was formulated as follows.
Let us denote the set of injections by I. I
j
k ∈ I, stands
for a single injection of one drug, where the upper index j
refers to the index of the injection day, and the lower index
k refers to the type of the drug. The injection day has to be
a treatment day: j ∈ D. If we denote the final volume of the
tumor with VF , we can formulate an optimization problem:
minVF subject to
∑
j
I
j
k ≤ 5 ∀ k (10)
I
j
k ≥ 0.1 ∀ (j, k) , (11)
where the last constraint corresponds to a minimal dose. We
used particle swarm optimization algorithm [20] to minimize
the the final volume of the tumor.
Table II summarizes the results corresponding to the
various treatment schedules. We can see in this table that
dosage optimization, compared to evenly distributed drug
dosage, brings a significant benefit. The final volume of
the tumor is 2.42 mm3 less in average assuming dosage
optimization.
schedule V EDDF V
OPT
F
S1 3.74417 3.43532
S2 3.57614 3.04489
S3 3.373 2.8845
S4 3.33873 3.10594
S5 3.51775 3.50207
S6 3.20646 3.11058
S7 3.1868 2.89367
S8 3.08598 3.04568
S9 3.24594 3.27486
S10 2.97913 2.78181
S11 2.953 2.83257
S12 3.10155 2.96291
S13 2.95682 2.78619
S14 2.91386 2.81943
S15 3.04249 3.00457
S16 3.48436 3.01904
S17 3.44582 3.05901
S18 3.38522 3.1209
S19 3.47586 3.30923
S20 3.2013 2.93869
S21 3.33681 2.88724
S22 3.43901 3.0496
S23 3.19762 2.81744
S24 3.31033 2.85308
S25 3.31543 2.98908
S26 2.98729 2.93036
S27 3.07179 2.88182
S28 3.05811 3.08618
S29 3.00501 2.84769
S30 3.16397 2.86673
S31 3.18932 3.00689
S32 2.84901 2.78173
S33 2.88932 2.85718
S34 3.01868 2.88544
S35 2.91295 2.70669
S36 3.43138 3.14631
S37 3.46217 2.97685
S38 3.43321 3.07804
S39 3.26424 2.8927
S40 3.33355 3.14728
S41 3.39184 2.93187
S42 3.1523 2.7935
S43 3.22266 2.81946
S44 3.17867 2.83988
S45 3.14733 2.81217
S46 3.0205 2.74971
S47 3.07113 2.9063
S48 3.12076 2.98946
S49 2.99687 2.88966
S50 2.94423 2.79583
S51 3.17074 2.85151
S52 3.21535 2.99286
S53 3.31029 2.94158
S54 3.25271 3.07257
S55 3.1615 2.95018
S56 3.10565 2.86805
S57 3.22568 2.95641
TABLE II
FINAL TUMOR VOLUME IN THE CASE OF VARIOUS TREATMENT
SCHEDULES, ASSUMING EVENLY DISTRIBUTED (V EDDF ) VS. OPTIMIZED
( V OPTF ) DRUG DOSAGE
As one may see in Table II, the most efficient open-loop
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therapy may be achieved with protocol S35. In this case the
patient receives injections on days 12, 14 and 16 and the
dosage is described in equation (12).
I
12
AA = 2.36 I
14
AA = 2.06 I
16
AA = 0.58
I
12
CT = 1.13 I
14
CT = 0.33 I
16
CT = 3.54 (12)
The final tumor volume is 2.707 mm3, while the drug
concentrations resulting from the optimized injections are
depicted in Fig. 3.
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Fig. 3. Plasma drug concentrations in the case of the optimized dosage
open-loop protocol.
D. Closed-loop therapy
The main motivation of the original bi-compartmental
model [17] was the assumption that in the near future,
biological markers which allow the estimation of the created
state variables will be available for on-line measurements.
Assuming valid estimations for the state variables, different
feedback laws can be designed for therapeutic purposes; fur-
thermore, these closed-loop therapies will have the potential
to be implemented when carry-on devices will be available
for continuous administration of the drugs, as in the case of
the artificial pancreas [13].
We introduce two heuristic proportional static feedback
laws corresponding to the two drugs, based on biological
considerations.
• The feedback of the antiangiogenic drug: As the process
of angiogenesis is dependent on tumor angiogenesis
factor (TAF) – the target of the antiangiogenic drug–,
it is straightforward to assume that its inhibition makes
sense only if TAF is present. As the function fTAF
describes the secretion rate of TAF by living tumor cells,
it seems plausible to implement a feedback which is
proportional to this normalized function as follows:
IAA(t) = KAAfTAF ([NC(t)]) , (13)
where KAA is the corresponding feedback gain.
• The feedback of the cytotoxic drug: As the normalized
actual growth rate function g([TP ]), depending on the
tumor cell concentration in the periphery is a key
element of tumor growth, and reflects the actual growth
rate, it seems plausible to ’punish’ the tumor growth
with the administration of cytotoxic drugs and formulate
the corresponding feedback law as follows:
ICT (t) = KCT g([TP ]) (14)
where KCT is the corresponding feedback gain.
Consequently, we consider two scenarios in the closed-
loop case.
1) Limitation of the total injected drug amount: We
investigate the case when the total injected amount of drugs
in the closed-loop therapy is equal to the injection amount
of the open-loop protocol (thus the total injection amount
of both drugs is 5 units). As the simulations show that
the total injected amount is a monotone increasing function
of the feedback gain in the case of both drugs, we may
easily determine feedback gains which result in this quantity,
namely, KAA = 0.556 and KCT = 0.633. Considering these
feedback gains, the plasma drug concentrations will evolve
as depicted in Fig. 4. This protocol results in the final tumor
size of 3721 mm3.
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Fig. 4. The resulting plasma drug concentrations in the case of closed-loop
administration, if the total injected quantity is equal to the open-loop case.
2) Limitation of the maximal plasma drug concentra-
tion: From a pharmacotherapeutical point of view, maximal
plasma concentration during the therapy can be used as
quantification of drug load. In the optimal S35 open-loop
therapy, maximal plasma concentration of the antiangiogenic
drug is 3.7 mg/kg, and maximal plasma concentration of
the cytotoxic drug is 4.2 mg/kg. Considering this therapy
as basis to determine the feedback gains, we get the values
KAA = 0.98 and KCT = 2.05. The dynamics of the drugs
are depicted in Fig. 5 in this case.
As we can see in Fig. 5, neither of the drugs exceed the
reference plasma concentrations. However, as the constant
injection has to balance out clearance in this case, the total
injected amounts are 13.39 units and 12.85 units for the
antiangiogenic and for the cytotoxic drug respectively, which
are significantly more compared to the original value of 5
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Fig. 5. The resulting plasma drug concentrations in the case of closed-loop
administration, if maximal plasma concentrations are equal to the open-loop
case.
units. The final volume of the tumor however is only 1879
mm3, which is only about 69% of the value obtained by
optimal open-loop therapy.
IV. CONCLUSIONS AND FUTURE WORK
In this paper, we extended the original model described
in [17] with an additional input to make it able to account
for cytotoxic drug application as well (in addition to the
administration of angiogenic inhibitor). We have compared
the effect of the two inputs to the dynamics of the model, and
derived the optimal instance of one-shot therapy protocols for
a reference drug injection value (5 units).
Regarding the open-loop protocol, we have formulated
a simple drug-dosage optimization problem with a fixed
number of injection days, and solved it with the help of
numerical optimization. In addition, we analyzed a heuris-
tic proportional static feedback law. If we constrained the
total injected drug quantity, the proposed feedback control
resulted in the final tumor size of 3721 mm3, which is
equal to approximately 134% of the value obtained by the
optimization of the open-loop protocol. On the other hand,
if we constrained the maximal plasma concentration of the
injected drugs according to the optimal scenario in the open-
loop approach, the final volume of the tumor reduced to 1879
mm3, which is only about 69% of the optimal open-loop
reference value. This result clearly shows the potential of
closed-loop approaches according to model predictions.
We have to note that the model [17] has been validated
only with tumor volume measurements, and not yet with
dynamical vasculature data, so its predictions must be con-
sidered in the light of this. However, on the other hand we,
are not aware of any dynamical model in the literature which
would have been validated against such explicit data.
In the future, we will focus on robustness analysis as a
straightforward continuation of the work performed in this
article. As the main expectation of closed-loop control is
to cancel out model uncertainties at considerable level, it
would be desirable to study how parametric changes affect
the optimality of open- and closed-loop approaches.
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